End testing on dogs and other animals for development of products for human use

Many tests on dogs and other animals cause unimaginable suffering. They can translate poorly into effective treatments and cures for human diseases or provide safety and efficacy data that is not relevant to humans.

Over 90% of drugs that appear safe and effective in animals do not go on to receive FDA, USA approval.

In 2023, 2,605,528 animals were used for the first time in scientific procedures incl. 2,477 dogs & 1,815 primates. Animals are bred & housed in bleak conditions and then used in tests that can cause immense physical and psychological suffering. We think government-led action is required to radically divert funding and evolve policy to implement the use of existing and the development of new Non-Animal Methodologies (NAMS). We believe the current testing paradigm is failing both animals and humans and is holding back medical advances.

Our published Replacing Animals in Science strategy (https://www.gov.uk/government/publications/replacing-animals-in-science-strategy) will accelerate the roll out of safe and effective alternatives to phase out animal testing in all but exceptional circumstances, delivering on our manifesto pledge to “partner with scientists, industry, and civil society as we work towards the phasing out of animal testing". By streamlining the process for bringing alternatives forward, the Government will accelerate our transition away from animal use, while continuing to support crucial research and innovation.

Scientific advances make the prospects for change better than they have ever been, and we are supporting the acceleration of advances in biomedical science and technologies, to reduce reliance on the use of animals in research. This includes stem cell research, cell culture systems that mimic the function of human organs, imaging and new computer modelling and AI techniques based on very large data sets.

The strategy is backed by £75m of funding to accelerate safe and effective alternative methods, including £30m for the UK Centre for the Validation of Alternative Methods (UKCVAM) – a new centre to make the path to regulatory approval for new alternatives as straightforward as possible. It also includes £30m for a preclinical translational models hub – an institute that will bring together data, technology and expertise to promote collaboration between researchers.

The strategy includes a target that aims to use validated alternative methods to reduce the use of dogs and non-human primates in dedicated pharmacokinetic (PK) studies for human medicines by at least 35% by 2030. The strategy also sets a target to aim to use validated alternative methods to reduce the use of non-human primates and dogs in dedicated cardiovascular safety studies by at least 50% by 2030.